Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 0.22 a new company low.

Within Biotechnology & Pharmaceuticals industry 137 other companies have achieved higher Quick Ratio than Opthea Limited in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 0 to 2932.

Explain Quick Ratio?
How much Cash & cash equivalents OPT�s has?
What are OPT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

OPT Quick Ratio	(Jun 30 2025) Q4	0 Q3	0 Q2	0 Q1	(Jun 30 2024) Q4
Y / Y Current Liabilities Change	302.57 %	302.57 %	161.95 %	302.57 %	241.77 %
Y / Y Cash & cash equivalent Change	-69.58 %	-69.58 %	-69.58 %	-69.58 %	92.26 %
Quick Ratio MRQ	0.22	0.22	0.21	0.22	2.85
OPT's Total Ranking	# 2932	# 0	# 841	#	#
Seq. Current Liabilities Change	0 %	-3.64 %	3.78 %	302.57 %	0 %
Seq. Cash & cash equivalent Change	0 %	0 %	0 %	-69.58 %	0 %

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 138
Healthcare Sector	# 800
Overall Market	# 2932

Quick Ratio Statistics
High	Average	Low
39.65	11.95	0.22
(Jun 30 2021)		(Jun 30 2025)

Financial Statements
Opthea Limited's Current Liabilities	$ 258 Millions	Visit OPT's Balance sheet
Opthea Limited's Cash & cash equivalent	$ 56 Millions	Visit OPT's Balance sheet
Source of OPT's Sales		Visit OPT's Sales by Geography

Cumulative Opthea Limited's Quick Ratio

OPT's Quick Ratio for the trailling 12 Months

OPT Quick Ratio	(Jun 30 2025) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Jun 30 2024) 12 Months
Y / Y Current Liabilities TTM Growth	253.76 %	240.3 %	220.85 %	253.28 %	216.95 %
Y / Y Cash & cash equivalent TTM Growth	-69.58 %	-45.67 %	-14.2 %	29.05 %	92.26 %
Quick Ratio TTM	0.21	0.41	0.73	1.24	2.49
Total Ranking TTM	# 3083	# 0	# 3375	#	#
Seq. Current Liabilities TTM Growth	22.87 %	29.65 %	33.89 %	65.85 %	18.2 %
Seq. Cash & cash equivalent TTM Growth	-36.38 %	-26.67 %	-21.06 %	-17.39 %	13.63 %

Quick ratio ranking by company, industry and sector >> Back to OPT Financial Strength Comparisons >> Go to Compare OPT Quick Ratio to its Competitors

News about Opthea Limited Quick Ratio

Opthea Secures $35M Commitment and Secures Additional $50M Funding to Revolutionize Treatment for Retinal Diseases

Opthea Limited, a clinical-stage biopharmaceutical company focused on developing innovative therapies for retinal diseases, has announced that it is set to receive the remaining $35 million in committed funds under its Development Funding Agreement (DFA) with Carlyle and Abingworth. Additionally, the company has finalized binding documentation with a new co-investor, securing an additional $50 million in funding.
This injection of funds will provide Opthea with substantial financial support to advance its research and development efforts. Known for their commitment to addressing highly prevalent and progressive retinal diseases, Opthea aims to develop groundbreaking therapies that can provide hope to millions of patients worldwide.

On the trailing twelve months basis Due to unchanged in Current Liabilities in the Q4 2025 to $257.87 millions, cumulative Quick Ratio decreased to 0.21 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 142 other companies have achieved higher Quick Ratio than Opthea Limited. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 0 to 3083.

Explain Quick Ratio?
How much Cash & cash equivalents OPT�s has?
What are OPT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 143
Healthcare Sector	# 844
Within the Market	# 3083

trailing twelve months Quick Ratio Statistics
High	Average	Low
39.65	12.01	2.85
(Jun 30 2021)		(Jun 30 2024)

Companies with similar Quick Ratio in the quarter ending Jun 30 2025, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Jun 30 2025 MRQ Cash & cash equivalent	Jun 30 2025 MRQ Current Liabilities
Scinai Immunotherapeutics Ltd	0.57	$ 0.989 Millions	$ 1.750 Millions
Curis Inc	0.56	$ 10.138 Millions	$ 18.107 Millions
Sab Biotherapeutics Inc	0.54	$ 5.714 Millions	$ 10.677 Millions
Dbv Technologies S a	0.53	$ 29.371 Millions	$ 55.647 Millions
Adaptimmune Therapeutics Plc	0.51	$ 26.061 Millions	$ 51.513 Millions
Halozyme Therapeutics Inc	0.46	$ 61.861 Millions	$ 134.282 Millions
Cellectis S a	0.41	$ 59.809 Millions	$ 145.458 Millions
Amgen Inc	0.39	$ 8,028.000 Millions	$ 20,476.000 Millions
Outlook Therapeutics Inc	0.28	$ 8.901 Millions	$ 31.432 Millions
Biocardia Inc	0.27	$ 0.980 Millions	$ 3.642 Millions
Elutia Inc	0.25	$ 8.500 Millions	$ 33.548 Millions
Xtant Medical Holdings Inc	0.23	$ 6.923 Millions	$ 29.855 Millions
Mink Therapeutics Inc	0.22	$ 1.682 Millions	$ 7.657 Millions
Opthea Limited	0.22	$ 55.630 Millions	$ 257.868 Millions
Tradeup Acquisition Corp	0.14	$ 1.317 Millions	$ 9.099 Millions
Liminatus Pharma Inc	0.13	$ 1.338 Millions	$ 10.516 Millions
Windtree Therapeutics Inc	0.11	$ 1.701 Millions	$ 15.721 Millions
Atlantic Coastal Acquisition Corp Ii	0.10	$ 2.080 Millions	$ 20.430 Millions
Brainstorm Cell Therapeutics inc	0.10	$ 0.824 Millions	$ 8.528 Millions
Tevogen Bio Holdings Inc	0.09	$ 0.685 Millions	$ 7.754 Millions
Aim Immunotech Inc	0.08	$ 0.835 Millions	$ 10.160 Millions
Zeo Scientifix Inc	0.08	$ 0.314 Millions	$ 3.875 Millions
Aptose Biosciences Inc	0.07	$ 0.600 Millions	$ 8.293 Millions
Vaxart Inc	0.05	$ 6.160 Millions	$ 117.878 Millions

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.